TY - JOUR
T1 - Validation methods for encapsulated faecal microbiota transplantation
T2 - a scoping review
AU - Rågård, Nina
AU - Baumwall, Simon Mark Dahl
AU - Paaske, Sara Ellegaard
AU - Hansen, Mette Mejlby
AU - Høyer, Katrine Lundby
AU - Mikkelsen, Susan
AU - Erikstrup, Christian
AU - Dahlerup, Jens Frederik
AU - Hvas, Christian Lodberg
PY - 2025/1/1
Y1 - 2025/1/1
N2 - A comprehensive evaluation of quality aspects to consider when developing encapsulated donor faeces for faecal microbiota transplantation Faecal microbiota transplantation (FMT) is a life-saving therapy, based on the transfer of intestinal microbiota from a healthy donor to a patient to treat disease. Encapsulation of donor faeces eases the application of FMT, but methods to evaluate the quality of encapsulated FMT are not standardised. Based on a systematic literature review, we here provide a comprehensive overview of factors that may influence the quality of encapsulated FMT. We describe three main domains that together form a model for standardisation: 1. Processing (donor selection and processing protocol), 2. Content analysis (microbiota measures and dose measures) and 3. Clinical effect (engraftment and clinical outcomes). These domains may be addressed in future studies that report the use of encapsulated FMT.
AB - A comprehensive evaluation of quality aspects to consider when developing encapsulated donor faeces for faecal microbiota transplantation Faecal microbiota transplantation (FMT) is a life-saving therapy, based on the transfer of intestinal microbiota from a healthy donor to a patient to treat disease. Encapsulation of donor faeces eases the application of FMT, but methods to evaluate the quality of encapsulated FMT are not standardised. Based on a systematic literature review, we here provide a comprehensive overview of factors that may influence the quality of encapsulated FMT. We describe three main domains that together form a model for standardisation: 1. Processing (donor selection and processing protocol), 2. Content analysis (microbiota measures and dose measures) and 3. Clinical effect (engraftment and clinical outcomes). These domains may be addressed in future studies that report the use of encapsulated FMT.
KW - capsules administration and dosage
KW - faecal microbiota transplantation methods
KW - faeces
KW - humans
KW - microbiology
KW - validation studies
UR - http://www.scopus.com/inward/record.url?scp=85217158801&partnerID=8YFLogxK
U2 - 10.1177/17562848251314820
DO - 10.1177/17562848251314820
M3 - Review
C2 - 39926318
SN - 1756-283X
VL - 18
JO - Therapeutic Advances in Gastroenterology
JF - Therapeutic Advances in Gastroenterology
ER -